Mark your calendars for Wednesday 6th November 2024, as Recursion Pharmaceuticals (NASDAQ: RXRX) is set to unveil its third quarter financial results. This highly anticipated announcement will be made after market close, giving investors and market participants a chance to assess the company's financial performance.
According to the predictions of financial experts on Wall Street, the establishment is expected to announce an anticipated $0.35 loss per share for the quarter. Further, the firm is poised to disclose a total revenue of $29.84 million for the period.
During the equivalent quarter of the preceding year, the company's financial report highlighted a per-share loss of $0.43. This significant amount was the outcome of the company's total revenue, which reached an impressive $10.53 million during that particular timeframe.
According to the Wall Street analysts projections, the company is expected to generate a total revenue of $69 million for the fiscal year. Additionally, these analysts anticipate that the company will report loss of $1.62 per share during the same period.
Throughout Friday's trading, Recursion Pharmaceuticals (RXRX) shares fluctuated between $6.34 and $6.58, with a trading volume of 3.52 million shares. The stock ended the regular trading session at $6.40, indicating a gain of 1.27 percent.
